What happens to trust when the company changes hands?

A consumer can buy a genetic test to learn something personal and still create information valuable to a much larger research enterprise. That dual use creates opportunity and responsibility at the same time. 23andMe's business brought the distinction into public view when financial distress led to a court-supervised sale in 2025. The episode is best understood as a question about continuity of obligations, not a claim that all genetic research partnerships are improper or that participation has no value.

The company's securities filing records that it and subsidiaries sought Chapter 11 protection on March 23, 2025. The sale process involved assets that included its consumer genetics and research businesses. For customers, however, the stakes were not limited to the commercial value of those assets. The organization holding sensitive information could change. People who had agreed to a service or research arrangement had to understand what the transition meant for the commitments originally made to them.

The FTC chairman addressed that problem in a March 31 letter concerning the bankruptcy. He emphasized the company's privacy representations and the need to respect existing commitments in any sale or transfer. This was a regulator's statement of concern and expectations, not a finding that a particular completed transfer had violated the law. It identified a practical constraint on the transaction: information could not responsibly be treated as though the customer relationship and prior representations were irrelevant to its future use.

Associated Press reporting in July described court approval for a sale to TTAM Research Institute, the nonprofit led by cofounder Anne Wojcicki. It also reported continuing objections from some states and the buyer's stated privacy commitments. The later SEC filing records a July 14 closing for the consumer genetics and research assets. It distinguishes those assets from the telehealth business, which remained with the debtor at that point. Keeping the entities and dates separate prevents an oversimplified account of a single company being sold intact.

The central stakeholder problem was not solved by attaching a reassuring label to the buyer. Customers needed understandable choices. Researchers needed legitimate access and dependable provenance. The buyer needed a viable operation. Creditors sought value from the estate. Regulators and the court considered constraints on the transaction. These interests overlapped, but they did not collapse into one objective. A promise that data will be handled responsibly needs mechanisms that remain meaningful when ownership, incentives, and financial circumstances change.

Seen from the founder's position, data governance belongs inside the product's design from the outset. Consent categories, deletion processes, documentation, access controls, and transfer provisions shape what a company can legitimately do later. Designing them only for the optimistic case leaves the organization less prepared for a financing crisis or acquisition. This is not legal advice about a particular consent form. It is a strategic observation: the rights and expectations attached to information influence the range of future business choices.

A useful exercise is to imagine the business being sold to a buyer the original customer would not have anticipated. What would the customer reasonably expect to remain true? Which choices could they exercise in practice? What evidence would show that the promises traveled with the assets? The 2025 23andMe episode makes those questions concrete. The enduring asset is not merely a database. It is a relationship whose terms must remain intelligible and enforceable after the original pitch, founder, or corporate structure has changed.

For a discussion tailored to your team, explore a workshop with Julien.